Identification of Risk Factors for Recurrence in High-risk Stage II Colon Cancer

Overview

Journal Int Surg

Specialty General Surgery

Date 2013 May 25

PMID 23701145

Citations 9

Authors

Satoshi Hatano

Hideyuki Ishida

Keiichiro Ishibashi

Kensuke Kumamoto

Norihiro Haga

Ichiro Miura

Affiliations

Soon will be listed here.

Abstract

To identify risk factors for recurrence in patients with stage II colon cancer, Cox proportional hazards regression analysis was performed in 194 patients with stage II colon cancer who underwent curative surgery between April 1997 and December 2008. Thirteen clinical and pathologic factors, including use of fluoropyrimidine-based adjuvant chemotherapy in 113 of the patients (58.2%), were assessed. By multivariate analysis, only obstruction, perforation, and T4-level invasion were identified as independent risk factors affecting disease-free survival (DFS) (P < 0.01). The 5-year DFS rate was 70.6% in patients with one or more risk factors (n = 68) and 96.0% in patients with no risk factors (n = 126) (P < 0.01). These results suggest that obstruction, perforation, and T4-level invasion are suitable candidates for prediction of tumor recurrence in patients with stage II colon cancer. The oxaliplatin-based adjuvant chemotherapy, which has been reported to be effective in stage III colon cancer patients, may improve the prognosis in high-risk stage II colon cancer patients.

Citing Articles

Prognostic and Predictive Determinants of Colorectal Cancer: A Comprehensive Review.

Cotan H, Emilescu R, Iaciu C, Orlov-Slavu C, Olaru M, Popa A Cancers (Basel). 2024; 16(23).

PMID: 39682117 PMC: 11640109. DOI: 10.3390/cancers16233928.

The utility of surveillance CT scans in a cohort of survivors of colorectal cancer.

Braden J, Blinman P, Malalasekera A, Kerin-Ayres K, Spencer J, Southi N J Cancer Surviv. 2022; 17(4):1202-1210.

PMID: 35040075 DOI: 10.1007/s11764-021-01155-y.

Early postoperative recurrences for colon cancer: Results from a Pakistani rural cohort.

Khan S, Fatima I J Taibah Univ Med Sci. 2020; 15(3):232-237.

PMID: 32647519 PMC: 7336005. DOI: 10.1016/j.jtumed.2020.03.004.

Colorectal carcinogenesis: Insights into the cell death and signal transduction pathways: A review.

Pandurangan A, Divya T, Kumar K, Dineshbabu V, Velavan B, Sudhandiran G World J Gastrointest Oncol. 2018; 10(9):244-259.

PMID: 30254720 PMC: 6147765. DOI: 10.4251/wjgo.v10.i9.244.

Colorectal obstruction is a potential prognostic factor for stage II colorectal cancer.

Okuda Y, Shimura T, Yamada T, Hirata Y, Yamaguchi R, Sakamoto E Int J Clin Oncol. 2018; 23(6):1101-1111.

PMID: 29948240 DOI: 10.1007/s10147-018-1307-2.

References

Chua W, Goldstein D, Lee C, Dhillon H, Michael M, Mitchell P . Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer. Br J Cancer. 2009; 101(6):998-1004. PMC: 2743363. DOI: 10.1038/sj.bjc.6605239. View

Javle M, Hsueh C . Recent advances in gastrointestinal oncology--updates and insights from the 2009 annual meeting of the American society of clinical oncology. J Hematol Oncol. 2010; 3:11. PMC: 2856525. DOI: 10.1186/1756-8722-3-11. View

Des Guetz G, Schischmanoff O, Nicolas P, Perret G, Morere J, Uzzan B . Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. Eur J Cancer. 2009; 45(10):1890-6. DOI: 10.1016/j.ejca.2009.04.018. View

Takagawa R, Fujii S, Ohta M, Nagano Y, Kunisaki C, Yamagishi S . Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Surg Oncol. 2008; 15(12):3433-9. DOI: 10.1245/s10434-008-0168-8. View

Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T . Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350(23):2343-51. DOI: 10.1056/NEJMoa032709. View

Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y . Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol. 2011; 17(1):1-29. DOI: 10.1007/s10147-011-0315-2. View

Gangadhar T, Schilsky R . Molecular markers to individualize adjuvant therapy for colon cancer. Nat Rev Clin Oncol. 2010; 7(6):318-25. DOI: 10.1038/nrclinonc.2010.62. View

Labianca R, Nordlinger B, Beretta G, Brouquet A, Cervantes A . Primary colon cancer: ESMO Clinical Practice Guidelines for diagnosis, adjuvant treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5:v70-7. DOI: 10.1093/annonc/mdq168. View

Perez R, Sao Juliao G, Habr-Gama A, Kiss D, Proscurshim I, Campos F . The role of carcinoembriogenic antigen in predicting response and survival to neoadjuvant chemoradiotherapy for distal rectal cancer. Dis Colon Rectum. 2009; 52(6):1137-43. DOI: 10.1007/DCR.0b013e31819ef76b. View

10.

Pihl E, Malahy M, Khankhanian N, Hersh E, Mavligit G . Immunomorphological features of prognostic significance in Dukes' Class B colorectal carcinoma. Cancer Res. 1977; 37(11):4145-9. View

11.

Compton C, Greene F . The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin. 2004; 54(6):295-308. DOI: 10.3322/canjclin.54.6.295. View

12.

Zaanan A, Cuilliere-Dartigues P, Guilloux A, Parc Y, Louvet C, de Gramont A . Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol. 2009; 21(4):772-780. DOI: 10.1093/annonc/mdp383. View

13.

Chun P, Wainberg Z . Adjuvant Chemotherapy for Stage II Colon Cancer: The Role of Molecular Markers in Choosing Therapy. Gastrointest Cancer Res. 2010; 3(5):191-6. PMC: 2806802. View

14.

Engstrom P, Arnoletti J, Benson 3rd A, Chen Y, Choti M, Cooper H . NCCN Clinical Practice Guidelines in Oncology: rectal cancer. J Natl Compr Canc Netw. 2009; 7(8):838-81. DOI: 10.6004/jnccn.2009.0057. View

15.

Swanson R, Compton C, Stewart A, Bland K . The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol. 2003; 10(1):65-71. DOI: 10.1245/aso.2003.03.058. View

16.

Benson 3rd A, Schrag D, Somerfield M, Cohen A, Figueredo A, Flynn P . American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol. 2004; 22(16):3408-19. DOI: 10.1200/JCO.2004.05.063. View

17.

Kuebler J, Wieand H, OConnell M, Smith R, Colangelo L, Yothers G . Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007; 25(16):2198-204. DOI: 10.1200/JCO.2006.08.2974. View

18.

Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C . Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009; 27(19):3109-16. DOI: 10.1200/JCO.2008.20.6771. View

19.

Ogata Y, Murakami H, Sasatomi T, Ishibashi N, Mori S, Ushijima M . Elevated preoperative serum carcinoembrionic antigen level may be an effective indicator for needing adjuvant chemotherapy after potentially curative resection of stage II colon cancer. J Surg Oncol. 2008; 99(1):65-70. DOI: 10.1002/jso.21161. View

20.

Roth A, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D . Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2009; 28(3):466-74. DOI: 10.1200/JCO.2009.23.3452. View